Data from T-DM1 breast cancer trial released
Roche and its partner, ImmunoGen Inc, said Phase 2 data for their antibody-drug conjugate, T-DM1, in patients with metastatic breast cancer showed better progression-free survival than those on trastuzumab and chemotherapy.